Danimer Scientific Modifies 2023 Adjusted EBITDA Guidance To Range Of $(40)M-$(37)M Vs. Prior View Of Low End Of $(23)M-$(31)M
Portfolio Pulse from Benzinga Newsdesk
Danimer Scientific has revised its 2023 Adjusted EBITDA guidance, now expecting a range of $(40)M to $(37)M, compared to the previously anticipated low end of $(23)M to $(31)M.
November 14, 2023 | 9:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Danimer Scientific has lowered its 2023 Adjusted EBITDA outlook, indicating a potential increase in losses.
The revision of EBITDA guidance by Danimer Scientific to a lower range suggests that the company is expecting to face greater financial challenges than previously anticipated. This negative adjustment is likely to be viewed unfavorably by investors, potentially leading to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100